Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma

Hepatology

Volumn 58, Issue 1, 2013, Pages 171-181

  Long, Xi Dai ^a,b   Yao, Jin Guang ^b   Zeng, Zhi ^c   Ma, Yun ^d   Huang, Xiao Ying ^b   Wei, Zhong Hua ^e   Liu, Min ^e   Zhang, Jian Jun ^a   Xue, Feng ^a   Zhai, Bo ^a   Xia, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YOUJIANG MEDICAL COLLEGE FOR NATIONALITIES   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e Jinshan Branch   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; XRCC4 PROTEIN;

ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; GENETIC CODE; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AFLATOXIN B1; CARCINOMA, HEPATOCELLULAR; DNA ADDUCTS; DNA-BINDING PROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879607114     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26311     Document Type: Article

References (38)

1. Ren JS, Chen WQ, Shin HR, Ferlay J, Saika K, Zhang SW, Bray F. A comparison of two methods to estimate the cancer incidence and mortality burden in China in 2005. Asian Pac J Cancer Prev 2010; 11: 1587-1594.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Long XD, Yao JG, Zeng Z, Huang CH, Huang ZS, Huang YZ, etal. DNA repair capacity-related to genetic polymorphisms of DNA repair genes and aflatoxin B1-related hepatocellular carcinoma among Chinese population. In: Kruman I, ed. DNA Repair. Rijeka: InTech; 2011: 505-524.
4. Wang JS, Groopman JD. DNA damage by mycotoxins. Mutat Res 1999; 424: 167-181.
5. Pastwa E, Blasiak J. Non-homologous DNA end joining. Acta Biochim Pol 2003; 50: 891-908.
6. Wu PY, Frit P, Meesala S, Dauvillier S, Modesti M, Andres SN, etal. Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRCC4. Mol Cell Biol 2009; 29: 3163-3172.
7. Wu CN, Liang SY, Tsai CW, Bau DT. The role of XRCC4 in carcinogenesis and anticancer drug discovery. Recent Pat Anticancer Drug Discov 2008; 3: 209-219.
8. Tseng HC, Tsai MH, Chiu CF, Wang CH, Chang NW, Huang CY, etal. Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res 2008; 28: 1687-1691.
9. Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. HEPATOLOGY 2010; 52: 1301-1309.
10. Long XD, Ma Y, Zhou YF, Yao JG, Ban FZ, Huang YZ, Huang BC. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer 2009; 9: 400.
11. Long XD, Ma Y, Wei YP, Deng ZL. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res 2006; 36: 48-55.
12. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, etal. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996; 59: 128-134.
13. Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe S, Thomas N, Cooper DN. Human gene mutation database-a biomedical information and research resource. Hum Mutat 2000; 15: 45-51.
14. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
15. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis 2002; 23: 381-387.
16. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366: 23-44.
17. CSLC, CSCO. Diagnosis and treatment of primary liver cancer: a standardized expert consensus. Chinese Clinical Oncology 2009; 14: 259-269.
18. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, Wang HY. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer 2011; 117: 3363-3373.
19. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-510.
20. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48( Suppl 1): S20-S37.
21. Habib SL, Said B, Awad AT, Mostafa MH, Shank RC. Novel adenine adducts, N7-guanine-AFB1 adducts, and p53 mutations in patients with schistosomiasis and aflatoxin exposure. Cancer Detect Prev 2006; 30: 491-498.
22. Johnson WW, Guengerich FP. Reaction of aflatoxin B1 exo-8, 9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc Natl Acad Sci U S A 1997; 94: 6121-6125.
23. Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM, etal. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. HEPATOLOGY 2010; 52: 2034-2043.
24. Dominguez-Malagon H, Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol 2001; 25: 497-516.
25. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007; 37: 389-396.
26. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 962-971.
27. Long XD, Ma Y, Deng ZL. GSTM1 and XRCC3 polymorphisms: effects on levels of aflatoxin B1-DNA adducts. Chinese J Cancer Res 2009; 21: 177-184.
28. Pardo B, Gomez-Gonzalez B, Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci 2009; 66: 1039-1056.
29. Long XD, Ma Y, Qu de Y, Liu YG, Huang ZQ, Huang YZ, etal. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann Epidemiol 2008; 18: 572-578.
30. Mari PO, Florea BI, Persengiev SP, Verkaik NS, Bruggenwirth HT, Modesti M, etal. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A 2006; 103: 18597-18602.
31. van Heemst D, Brugmans L, Verkaik NS, van Gent DC. End-joining of blunt DNA double-strand breaks in mammalian fibroblasts is precise and requires DNA-PK and XRCC4. DNA Repair (Amst) 2004; 3: 43-50.
32. Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, etal. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability, and development. Nature 2000; 404: 897-900.
33. Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, etal. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95: 891-902.
34. Cahill D, Connor B, Carney JP. Mechanisms of eukaryotic DNA double strand break repair. Front Biosci 2006; 11: 1958-1976.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
36. Kim S, Kim T. Selection of optimal internal controls for gene expression profiling of liver disease. Biotechniques 2003; 35: 456-458, 460.
37. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72: 3641-3647.
38. Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, etal. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997; 18: 1291-1297.